← boardnext 2029-11-30
TERN
Terns, Inc.distress 0/10 · well-funded / low risk$52.950%today0% from 52w high
Lead: Chronic Myeloid Leukemia · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$1019M
Runway
12.4 yrs
Shares 1y
—
Price & events
+47.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.6%
1M
+40.2%
3M
+186.7%
6M
+1650.4%
1Y
—
2Y
—
5Y
+833.9%
All
Overview
- Volume
- 0
- 52 Week Range
- $2.78 – $53.17
- Float Shares
- 115.12M
- Short %
- 6.99%
- % Held by Insiders
- 0.25%
- % Held by Institutions
- 109.69%
- Beta
- -0.38
Pipeline stages · 1 programs
TERN-701
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-11-30 Estimated 50% readout ~2030-01-14 | Phase 1/2 | TERN-701 | Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia | — | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
hold · target $53 (+0% upside) · 4 analysts
- 2026-04-27OppenheimerOutperform → Perform
- 2026-04-14JP MorganOverweight
- 2026-03-31Truist SecuritiesBuy → Hold
- 2026-03-30BarclaysOverweight → Equal-Weight
- 2026-03-26CitizensMarket Outperform → Market Perform
- 2026-03-26TD CowenBuy → Hold
Competitors — Chronic Myeloid Leukemia
Recent news
- 2026-06-15Terns Pharmaceuticals Financial Outlook Raises Concerns Amid Market Trends - timothysykes.com
- 2026-06-15Terns Pharmaceuticals Holds Steady Near $53 Amid Tight Trading Range - Retail Driven Moves - dars.gov.et
- 2026-05-08[EFFECT] Terns Pharmaceuticals, Inc. SEC Filing - Stock Titan
- 2026-05-07Merck Acquires Terns Pharmaceuticals, Adds TERN-701 to Oncology Pipeline - Digital Health News
- 2026-05-06Terns Pharmaceuticals, Inc.(NasdaqGS: TERN) dropped from Russell 2000 Index - marketscreener.com
- 2026-05-05Merck completes purchase of Terns Pharmaceuticals Inc. - ROI-NJ
- 2026-05-05Merck completes acquisition of Terns - Breakingthenews.net
- 2026-05-05Merck Completes Acquisition of Terns Pharmaceuticals, Inc. - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.